Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Donepezil for REM Enhancement in Autism
NCT01887132Phase 2Terminated
- Sponsor
- National Institute of Mental Health
- Start
- Jun 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of donepezil in Autism Spectrum Disorder (ASD) (3 arms), sponsored by National Institute of Mental Health. Primary endpoint: Nonverbal Developmental Quotient at 12 months. Started Jun 2013; status: terminated.
02
Drugs
donepezil
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT01887132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01887132.